A Peptide Backbone Stapling Strategy Enabled by the Multicomponent Incorporation of Amide N‐Substituents
作者:Manuel G. Ricardo、Javiel F. Marrrero、Oscar Valdés、Daniel G. Rivera、Ludger A. Wessjohann
DOI:10.1002/chem.201805318
日期:2019.1.14
N‐modification of peptides on solid‐phase is presented as a powerful and general method to enable peptidestapling at the backbone instead of the side chains. This work shows that a variety of functionalized N‐substituents suitable for backbone stapling can be readily introduced by means of on‐resin Ugi multicomponent reactions conducted during solid‐phase peptide synthesis. Diverse macrocyclization chemistries
Metal-Chelating Inhibitors of a Zinc Finger Protein HIV-EP1. Remarkable Potentiation of Inhibitory Activity by Introduction of SH Groups
作者:Mikako Fujita、Masami Otsuka、Yukio Sugiura
DOI:10.1021/jm950831t
日期:1996.1.1
HIV-EP1 is a C2H2 type zinc finger proteinwhich binds to DNA kappa B site present in the long terminal repeat of HIV provirus. Previously we have reported zincchelators having histidine--pyridine--histidine skeleton and were successful in inhibiting the DNA binding of HIV-EP1 by removing zinc from the zinc finger domain. Aiming at the potentiation of the inhibitory activity of our previous zinc chelators
“Turn-on” FRET-based luminescent iridium(iii) probes for the detection of cysteine and homocysteine
作者:Hoi-Yan Shiu、Man-Kin Wong、Chi-Ming Che
DOI:10.1039/c0cc04288a
日期:——
âTurn-onâ FRET-based luminescent probes containing iridium(III) complexes for the detection of Cys and Hcy have been designed and synthesized. The relationship between the steric bulk of the probe and the corresponding emission intensity enhancement towards detection of Cys and Hcy has been studied.
[EN] PROTEIN CARRIER-LINKED PRODRUGS<br/>[FR] PROMÉDICAMENTS LIÉS À UN EXCIPIENT PROTÉIQUE
申请人:ASCENDIS PHARMA AS
公开号:WO2013024049A1
公开(公告)日:2013-02-21
The present invention relates to water-soluble protein carrier- linked prodrugs wherein the protein carrier comprises an amino acid sequence consisting of at least 100 amino acid residues forming random coil conformation and comprising alanine, serine and proline residues. It further relates to pharmaceutical compositions comprising said water-soluble protein carrier- linked prodrugs, their use as a medicament as well as methods of treatment and administration.